IGF2BP3 enhances ferroptosis resistance in colon cancer by stabilizing SLC7A11 and is regulated by miR-98-5p

PurposeColon cancer remains a global health challenge with rising mortality, necessitating novel therapeutic strategies. IGF2BP3, an oncogenic RNA-binding protein, is implicated in colon cancer progression, while its role in ferroptosis regulation remains unclear. This study investigates IGF2BP3’s r...

Full description

Saved in:
Bibliographic Details
Main Authors: Yaya Sun, Qingwei Liu, Junjie Wu, Guangqing Jiang, Hongzhou Shi, Yihong Zhang, Yanxuan Ling, Weimin Sun, Xin Shi, Congxing Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1576895/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849467936907984896
author Yaya Sun
Qingwei Liu
Junjie Wu
Guangqing Jiang
Hongzhou Shi
Yihong Zhang
Yanxuan Ling
Weimin Sun
Xin Shi
Congxing Liu
author_facet Yaya Sun
Qingwei Liu
Junjie Wu
Guangqing Jiang
Hongzhou Shi
Yihong Zhang
Yanxuan Ling
Weimin Sun
Xin Shi
Congxing Liu
author_sort Yaya Sun
collection DOAJ
description PurposeColon cancer remains a global health challenge with rising mortality, necessitating novel therapeutic strategies. IGF2BP3, an oncogenic RNA-binding protein, is implicated in colon cancer progression, while its role in ferroptosis regulation remains unclear. This study investigates IGF2BP3’s role in ferroptosis regulation and its interplay with miR-98-5p in colon cancer, aiming to identify therapeutic targets for enhancing ferroptosis sensitivity.MethodsBioinformatics analyses (TCGA, UALCAN, GEPIA) assessed IGF2BP3 expression and prognostic relevance in colon cancer. The expression of IGF2BP3 in clinical samples were analyzed via immunohistochemistry (IHC) and Western blotting. IGF2BP3-knockdown (KD) cell lines (HCT116/DLD-1) were generated using lentiviral shRNA. Ferroptosis sensitivity was evaluated via CCK-8 assays, MDA/ROS quantification, and rescue experiments with ferrostatin-1. Transcriptomic sequencing, RNA immunoprecipitation (RIP), and RNA stability assays identified IGF2BP3-regulated targets. Dual-luciferase reporter assays validated miR-98-5p-IGF2BP3 interactions. Xenograft models assessed in vivo tumor growth.ResultsIGF2BP3 was significantly upregulated in colon cancer tissues and correlated with advanced T-stage, higher clinical stage, and poor survival (p<0.05). Knockdown of IGF2BP3 enhanced erastin-induced ferroptosis sensitivity, marked by elevated MDA and ROS levels, reversible by ferrostatin-1. Mechanistically, IGF2BP3 stabilized SLC7A11 mRNA via direct binding and SLC7A11 overexpression rescued ferroptosis resistance in IGF2BP3-KD cells. miR-98-5p directly targeted IGF2BP3’s 3′-UTR, suppressing its expression and enhancing ferroptosis sensitivity. In vivo, IGF2BP3-KD suppressed tumor growth and reduced Ki67/SLC7A11 expression.ConclusionIGF2BP3 drives ferroptosis resistance in colon cancer by stabilizing SLC7A11 mRNA, while miR-98-5p antagonizes this pathway via IGF2BP3 downregulation. Targeting the miR-98-5p/IGF2BP3/SLC7A11 axis offers a promising therapeutic strategy to enhance ferroptosis sensitivity and improve colon cancer outcomes.
format Article
id doaj-art-e8597e35e2b242df9c569b3797ee8878
institution Kabale University
issn 2234-943X
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-e8597e35e2b242df9c569b3797ee88782025-08-20T03:25:59ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15768951576895IGF2BP3 enhances ferroptosis resistance in colon cancer by stabilizing SLC7A11 and is regulated by miR-98-5pYaya Sun0Qingwei Liu1Junjie Wu2Guangqing Jiang3Hongzhou Shi4Yihong Zhang5Yanxuan Ling6Weimin Sun7Xin Shi8Congxing Liu9School of Medicine, Southeast University, Nanjing, ChinaSchool of Medicine, Southeast University, Nanjing, ChinaSchool of Medicine, Southeast University, Nanjing, ChinaSchool of Medicine, Southeast University, Nanjing, ChinaDepartment of General Surgery, Affiliated Zhongda Hospital of Southeast University, Nanjing, ChinaSchool of Medicine, Southeast University, Nanjing, ChinaSchool of Medicine, Southeast University, Nanjing, ChinaDepartment of General Surgery, Xuyi County People’s Hospital, Huai’an, ChinaDepartment of General Surgery, Affiliated Zhongda Hospital of Southeast University, Nanjing, ChinaDepartment of General Surgery, Affiliated Zhongda Hospital of Southeast University, Nanjing, ChinaPurposeColon cancer remains a global health challenge with rising mortality, necessitating novel therapeutic strategies. IGF2BP3, an oncogenic RNA-binding protein, is implicated in colon cancer progression, while its role in ferroptosis regulation remains unclear. This study investigates IGF2BP3’s role in ferroptosis regulation and its interplay with miR-98-5p in colon cancer, aiming to identify therapeutic targets for enhancing ferroptosis sensitivity.MethodsBioinformatics analyses (TCGA, UALCAN, GEPIA) assessed IGF2BP3 expression and prognostic relevance in colon cancer. The expression of IGF2BP3 in clinical samples were analyzed via immunohistochemistry (IHC) and Western blotting. IGF2BP3-knockdown (KD) cell lines (HCT116/DLD-1) were generated using lentiviral shRNA. Ferroptosis sensitivity was evaluated via CCK-8 assays, MDA/ROS quantification, and rescue experiments with ferrostatin-1. Transcriptomic sequencing, RNA immunoprecipitation (RIP), and RNA stability assays identified IGF2BP3-regulated targets. Dual-luciferase reporter assays validated miR-98-5p-IGF2BP3 interactions. Xenograft models assessed in vivo tumor growth.ResultsIGF2BP3 was significantly upregulated in colon cancer tissues and correlated with advanced T-stage, higher clinical stage, and poor survival (p<0.05). Knockdown of IGF2BP3 enhanced erastin-induced ferroptosis sensitivity, marked by elevated MDA and ROS levels, reversible by ferrostatin-1. Mechanistically, IGF2BP3 stabilized SLC7A11 mRNA via direct binding and SLC7A11 overexpression rescued ferroptosis resistance in IGF2BP3-KD cells. miR-98-5p directly targeted IGF2BP3’s 3′-UTR, suppressing its expression and enhancing ferroptosis sensitivity. In vivo, IGF2BP3-KD suppressed tumor growth and reduced Ki67/SLC7A11 expression.ConclusionIGF2BP3 drives ferroptosis resistance in colon cancer by stabilizing SLC7A11 mRNA, while miR-98-5p antagonizes this pathway via IGF2BP3 downregulation. Targeting the miR-98-5p/IGF2BP3/SLC7A11 axis offers a promising therapeutic strategy to enhance ferroptosis sensitivity and improve colon cancer outcomes.https://www.frontiersin.org/articles/10.3389/fonc.2025.1576895/fullIGF2BP3colon cancerferroptosismiR-98-5pSLC7A11
spellingShingle Yaya Sun
Qingwei Liu
Junjie Wu
Guangqing Jiang
Hongzhou Shi
Yihong Zhang
Yanxuan Ling
Weimin Sun
Xin Shi
Congxing Liu
IGF2BP3 enhances ferroptosis resistance in colon cancer by stabilizing SLC7A11 and is regulated by miR-98-5p
Frontiers in Oncology
IGF2BP3
colon cancer
ferroptosis
miR-98-5p
SLC7A11
title IGF2BP3 enhances ferroptosis resistance in colon cancer by stabilizing SLC7A11 and is regulated by miR-98-5p
title_full IGF2BP3 enhances ferroptosis resistance in colon cancer by stabilizing SLC7A11 and is regulated by miR-98-5p
title_fullStr IGF2BP3 enhances ferroptosis resistance in colon cancer by stabilizing SLC7A11 and is regulated by miR-98-5p
title_full_unstemmed IGF2BP3 enhances ferroptosis resistance in colon cancer by stabilizing SLC7A11 and is regulated by miR-98-5p
title_short IGF2BP3 enhances ferroptosis resistance in colon cancer by stabilizing SLC7A11 and is regulated by miR-98-5p
title_sort igf2bp3 enhances ferroptosis resistance in colon cancer by stabilizing slc7a11 and is regulated by mir 98 5p
topic IGF2BP3
colon cancer
ferroptosis
miR-98-5p
SLC7A11
url https://www.frontiersin.org/articles/10.3389/fonc.2025.1576895/full
work_keys_str_mv AT yayasun igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p
AT qingweiliu igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p
AT junjiewu igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p
AT guangqingjiang igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p
AT hongzhoushi igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p
AT yihongzhang igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p
AT yanxuanling igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p
AT weiminsun igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p
AT xinshi igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p
AT congxingliu igf2bp3enhancesferroptosisresistanceincoloncancerbystabilizingslc7a11andisregulatedbymir985p